OncoGenex Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 29,882 20,095 5,496 13,616
Cost of Revenue - - - -
Gross Profit 29,882 20,095 5,496 13,616
Operating Expenses
Research and Development 55,317 39,948 21,553 18,483
Sales, General and Admin. 9,892 7,791 6,230 5,840
Non-Recurring Items - (1,657) - 4,038
Other - - - -
Operating Income (35,327) (25,987) (22,287) (14,745)
Income From Continuing Operations
Add'l Income/Expense Items 3,478 4,889 7,614 (839)
Earnings Before Interest and Tax (31,849) (21,098) (14,673) (15,584)
Interest Expense - - - -
Earnings Before Tax (31,849) (21,098) (14,673) (15,584)
Income Tax - - - (3,000)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (31,849) (21,098) (14,673) (12,584)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (31,849) (21,098) (14,673) (12,584)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (31,849) (21,098) (14,673) (12,584)